Erratum: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Clinical Cancer Research (2019) 12(5199–5206)Doi:10.1158/1078-0432.CCR-06-0429)

Samuel K. Kulp, Chang Shi Chen, Da Sheng Wang, Ching Yu Chen, Ching Shih Chen

Research output: Contribution to journalComment/debatepeer-review

Fingerprint Dive into the research topics of 'Erratum: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Clinical Cancer Research (2019) 12(5199–5206)Doi:10.1158/1078-0432.CCR-06-0429)'. Together they form a unique fingerprint.

Medicine & Life Sciences